Related Experiment Video
Updated: Jul 30, 2025
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Medium-chain triglyceride-stabilized docetaxel-loaded HSA nanoparticles effectively inhibited metastatic non-small
Yunlong Cheng1, Xiaoying Pang2, Jing Wu1
1Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, Shanghai, 201203, China.
Abstract:
Metastatic non-small cell lung cancer (NSCLC) is refractory with a very poor prognosis. Docetaxel (DTX) injection (Taxotere®) has been approved for the treatment of locally advanced or metastatic NSCLC. However, its clinical application is restricted by severe adverse effects and non-selective tissue distribution. In this study, we successfully developed DTX-loaded human serum albumin (HSA) nanoparticles (DNPs) with modified Nab technology, by introducing medium-chain triglyceride (MCT) as a stabilizer. The optimized formulation had a particle size of approximately 130 nm and a favorable stabilization time of more than 24 h. DNPs dissociated in circulation in a concentration-dependent manner and slowly released DTX. Compared with DTX injection, DNPs were more effectively taken up by NSCLC cells, thus exerting stronger inhibitory effects on their proliferation, adhesion, migration, and invasion. In addition, DNPs showed prolonged blood retention and increased tumor accumulation relative to DTX injection. Ultimately, DNPs produced more potent inhibitory effects on primary or metastatic tumor foci than DTX injections but caused markedly lower organ toxicity and hematotoxicity. Overall, these results support that DNPs hold great potential for the treatment of metastatic NSCLC in clinical.
Insights
New human serum albumin nanoparticles loaded with docetaxel (DTX) show improved efficacy and reduced toxicity for metastatic non-small cell lung cancer (NSCLC) treatment.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Metastatic non-small cell lung cancer (NSCLC) presents a significant clinical challenge with poor prognosis.
- Current treatments like docetaxel (DTX) are limited by severe side effects and non-specific distribution.
Purpose of the Study:
- To develop and evaluate novel DTX-loaded human serum albumin (HSA) nanoparticles (DNPs) for improved NSCLC therapy.
- To assess the efficacy and safety profile of DNPs compared to conventional DTX injection.
Main Methods:
- Formulation of DTX-loaded HSA nanoparticles (DNPs) using modified Nab technology with medium-chain triglyceride (MCT) stabilization.
- Characterization of DNP particle size, stability, drug release kinetics, and cellular uptake.
- In vivo evaluation of DNP pharmacokinetics, tumor accumulation, anti-tumor efficacy, and organ/hematotoxicity in comparison to DTX injection.
Main Results:
- Optimized DNPs exhibited a particle size of ~130 nm and stability >24 hours, with controlled DTX release.
- DNPs demonstrated enhanced cellular uptake, leading to superior inhibition of NSCLC cell proliferation, adhesion, migration, and invasion.
- DNPs showed prolonged circulation, increased tumor accumulation, potent anti-tumor activity, and significantly reduced organ and hematotoxicity compared to DTX.
Conclusions:
- DTX-loaded HSA nanoparticles (DNPs) represent a promising drug delivery system for metastatic NSCLC.
- DNPs offer a potentially safer and more effective therapeutic strategy by enhancing drug targeting and reducing systemic toxicity.
More Related Videos
Related Concept Videos
01:15Drugs that Stabilize Microtubules
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...